NCT06185985View on ClinicalTrials.gov

Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

750

Participants

Timeline

Start Date

March 28, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions

Attention-Deficit/Hyperactivity Disorder

Interventions

DRUG

SPN-812

SPN-812 (200mg to 600mg once daily)

Trial Locations (1)

10001

ObvioHealth, New York

All Listed Sponsors

lead

Supernus Pharmaceuticals, Inc.

INDUSTRY